

**Supplementary Table 4a.** Appropriateness of the dose of the first NOAC prescription according to the EU drug label among patients with NVAF, stratified by previous use of an oral anticoagulant (naïve/non-naïve).

ALL NOACs	Naïve patients N=14,807 (48.6%)		Non-naïve N=15,660 (51.4%)		Total N=30,467	
	n	%	n	%	n	%
Appropriate dose	11,924	80.5	12,293	78.5	24,217	79.5
Inappropriate dose	2883	19.5	3367	21.5	6250	20.5

EU, European Union; NOAC, non-vitamin K antagonist oral anticoagulant; NVAF, non-valvular atrial fibrillation

**Supplementary Table 4b.** Appropriateness of the dose of the first apixaban prescription according to the EU drug label among patients with NVAF, stratified by previous use of an oral anticoagulant (naïve/non-naïve).

Apixaban	Naïve patients N=5774 (53.3%)		Non-naïve N=5060 (46.7%)		Total N=10,834	
	n	%	n	%	n	%
Appropriate dose	4405	76.3	3705	73.2	8110	74.9
Inappropriate dose	1369	23.7	1355	26.8	2724	25.1

EU, European Union; NOAC, non-vitamin K antagonist oral anticoagulant; NVAF, non-valvular atrial fibrillation

**Supplementary Table 4c.** Appropriateness of the dose of the first dabigatran prescription according to the EU drug label among patients with NVAF, stratified by previous use of an oral anticoagulant (naïve/non-naïve).

Dabigatran	Naïve patients N=1827 (41.7%)		Non-naïve N=2554 (58.3%)		Total N=4381	
	n	%	n	%	n	%
Appropriate dose	1383	75.7	1875	73.4	3258	74.4
Inappropriate dose	444	24.3	679	26.6	1123	25.6

EU, European Union; NOAC, non-vitamin K antagonist oral anticoagulant; NVAF, non-valvular atrial fibrillation

**Supplementary Table 4d.** Appropriateness of the dose of the first rivaroxaban prescription according to the EU drug label among patients with NVAF, stratified by previous use of an oral anticoagulant (naïve/non-naïve).

Rivaroxaban	Naïve patients N=7206 (47.2%)		Non-naïve N=8046 (52.8%)		Total N=15,252	
	n	%	n	%	n	%
Appropriate dose	6136	85.2	6713	83.4	12849	84.2
Inappropriate dose	1070	14.8	1333	16.6	2403	15.8

EU, European Union; NOAC, non-vitamin K antagonist oral anticoagulant; NVAF, non-valvular atrial fibrillation